(P007) Pooled Analysis of Locoregional Relapse After Minimally Invasive Surgery Alone for Intermediate- or High-Risk HPV+ Oropharyngeal Squamous Cell Carcinoma

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In the HPV+ population, ECE remains a significant risk factor for LRR without adjuvant therapy after MIS. Patients with intermediate-risk disease after MIS have moderate rates of LRR.

Ryan K. Funk, MD, David G. Stoddard, MD, Kanograt Tangsriwong, MD, Michael G. Keeney, MD, Qihui Zhai, MD, Eneida F. Vencio, DDS, Alexander Lin, MD, Joaquin J. Garcia, MD, Eric J. Moore, MD, Robert L. Foote, MD, Katharine A. Price, MD, Daniel J. Ma, MD; Department of Radiation Oncology, Department of Otolaryngology, Department of Laboratory Medicine and Pathology, Division of Medical Oncology, Mayo Clinic; Department of Radiation Oncology, University of Pennsylvania; Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL; Department of Oral Pathology, School of Dentistry, Federal University Goiás

PURPOSE/OBJECTIVES: Traditional risk factors predicting locoregional relapse (LRR) following surgery for head and neck squamous cell carcinomas were identified in the pre–human papillomavirus (HPV) era. Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) present at younger age and have an approximately 50% reduction in death when compared with their HPV− counterparts. Minimally invasive surgery (MIS) (eg, transoral robotic surgery [TORS] and transoral laser microsurgery [TLM]) allows for improved intraoperative assessment of the tumor. It is unknown if traditional risk factors fully apply to the HPV+ population that undergoes MIS. We examined whether traditional indications for adjuvant radiation therapy (RT) (perineural invasion [PNI], angiolymphatic invasion [ALI], T3–4, or N2a–b) or adjuvant chemoradiation therapy (CRT) (extracapsular extension [ECE] or positive margins) also predict for LRR in patients with HPV+ OPSCC who undergo MIS alone.

MATERIALS AND METHODS: After institutional review board (IRB) approval, the medical records of patients treated with TORS (two institutions) or TLM (one institution) for OPSCC were reviewed to identify patients with HPV+ tumors who had indications for adjuvant therapy but did not receive adjuvant therapy. HPV status was confirmed by p16 immunohistochemistry. Individual data from all three institutions were pooled into a single database for analysis.

RESULTS: A total of 43 patients with HPV+ base of tongue (n = 16) or tonsil (n = 27) OPSCC with a median age of 60 years (range: 37–81 yr) who did not receive adjuvant therapy despite the presence of intermediate- or high-risk features were identified. Seventeen of 43 patients had a smoking history > 10 pack-years. Fourteen patients had ECE as an indication for CRT. Margins were close in all patients due to the nature of MIS, but the final margins were all negative. Intermediate-risk features were ALI (n = 4), PNI (n = 3), T3 (n = 6), N2a (n = 13), and N2b (n = 6). Three patients had two intermediate risk factors. Median follow-up after surgery was 30.1 months (range: 3.1–161.7 mo). Eleven of 47 (26%) patients developed LRR at a median of 5.7 months (range: 2.9–39.2 mo). Kaplan-Meier estimate of 2-year relapse-free survival was lower for patients with ECE vs patients with intermediate-risk factors only (43% vs 88%, respectively; P = .02). LRR was detected locally (n = 3, base of tongue), locally and in ipsilateral regional lymph nodes (ILNs) (n = 1), in ILNs alone (n = 4), in contralateral regional LNs (n = 2), or in bilateral neck nodes (n = 1).

CONCLUSION: In the HPV+ population, ECE remains a significant risk factor for LRR without adjuvant therapy after MIS. Patients with intermediate-risk disease after MIS have moderate rates of LRR.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content